Format

Send to

Choose Destination
Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14.

iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.

Author information

1
Klinik I für Innere Medizin, Universität zu Köln, Cologne, Germany.
2
Center of Excellence for Cellular Stress Responses in Aging-Associated Diseases, Köln, Germany.
3
Lombardi Cancer Center, Georgetown University Hospital, Washington, DC.
4
Institute of Cancer Research, London, United Kingdom.
5
Department of Oncohematology, Universita Vita-Salute San Raffaele, Milan, Italy.
6
Institut Pasteur, Montevideo, Uruguay.
7
Department III of Internal Medicine, University of Ulm, Ulm, Germany.
8
St James's Institute of Oncology, Leeds, United Kingdom.
9
Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX.
10
Hospital Clinic, University of Barcelona, Barcelona, Spain.
11
Feinstein Institute for Medical Research, Manhasset, NY.
12
Division of Hematology, The Ohio State University, Columbus, OH.
13
Division of Hematology/Oncology, School of Medicine, University of California, Irvine, CA.
14
Department of Hematology, Medical University of Lodz, Lodz, Poland.
15
Peter MacCallum Cancer Centre, Royal Melbourne Hospital and University of Melbourne, Melbourne, Australia; and.
16
Rebecca and John Moores Cancer Center, University of California, San Diego, La Jolla, CA.

Abstract

The previous edition of the consensus guidelines of the International Workshop on Chronic Lymphocytic Leukemia (iwCLL), published in 2008, has found broad acceptance by physicians and investigators caring for patients with CLL. Recent advances including the discovery of the genomic landscape of the disease, the development of genetic tests with prognostic relevance, and the detection of minimal residual disease (MRD), coupled with the increased availability of novel targeted agents with impressive efficacy, prompted an international panel to provide updated evidence- and expert opinion-based recommendations. These recommendations include a revised version of the iwCLL response criteria, an update on the use of MRD status for clinical evaluation, and recommendations regarding the assessment and prophylaxis of viral diseases during management of CLL.

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center